Correlation between in vitro chemotherapy sensitivity and PARP-1 expression in patients with breast cancer.

被引：0
|
作者：
Liedtke, Cornelia
Packeisen, Jens
Denkert, Carsten
Kiesel, Ludwig
Vogt, Ulf
Mueller, Berit
Hess, Kenneth R.
Buerger, Horst
机构：
[1] Univ Munster, D-48149 Munster, Germany
[2] Inst Pathol, Osnabruck, Germany
[3] Charite, Inst Pathol, D-13353 Berlin, Germany
[4] Univ Hosp Munster, Munster, Germany
[5] European Lab Assoc, Ibbenburen, Germany
[6] Charite, D-13353 Berlin, Germany
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Inst Pathol, Paderborn, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10627
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Correlation between clinical tumor stiffness by elastography and response to neoadjuvant chemotherapy in patients with breast cancer.
    Hayashi, Mitsuhiro
    Yamamoto, Yutaka
    Sueta, Aiko
    Tomiguchi, Mai
    Fujiwara, Saori
    Yamamoto, Satoko
    Ina, Touko
    Ibusuki, Mutsuko
    Murakami, Kei-ichi
    Iwase, Hirotaka
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [12] Correlation of intratumor gene expression heterogeneity with chemotherapy sensitivity in breast cancer
    Natowicz, Rene
    Jiang, Tingting
    Shi, Weiwei
    Qi, Yuan
    Delpech, Yann
    Symmans, William Fraser
    Pusztai, Lajos
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [13] Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression
    Xiaobin Ma
    Chengxue Dang
    Weili Min
    Yan Diao
    Wentao Hui
    Xiaolong Wang
    Zhijun Dai
    Xijing Wang
    Huafeng Kang
    Breast Cancer Research and Treatment, 2019, 176 : 109 - 117
  • [14] Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression
    Ma, Xiaobin
    Dang, Chengxue
    Min, Weili
    Diao, Yan
    Hui, Wentao
    Wang, Xiaolong
    Dai, Zhijun
    Wang, Xijing
    Kang, Huafeng
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (01) : 109 - 117
  • [15] Implication of PARP-1 expression in prostate cancer progression.
    Thomas, E.
    Gannon, P. O.
    Koumakpayi, I. H.
    Latour, M.
    Mes-Masson, A.
    Saad, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [16] PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib
    Bianchi, Anna
    Lopez, Salvatore
    Altwerger, Gary
    Bellone, Stefania
    Bonazzoli, Elena
    Zammataro, Luca
    Manzano, Aranzazu
    Manara, Paola
    Perrone, Emanuele
    Zeybek, Burak
    Han, Chanhee
    Menderes, Gulden
    Ratner, Elena
    Silasi, Dan-Arin
    Huang, Gloria S.
    Azodi, Masoud
    Newberg, Justin Y.
    Pavlick, Dean C.
    Elvin, Julia
    Frampton, Garrett M.
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2019, 155 (01) : 144 - 150
  • [17] PARP-1 and γ-GCS inhibitors enhance platinum sensitivity in ovarian cancer
    Devi, Luxmi
    Sharma, Ashok
    Kumar, Lalit
    CANCER RESEARCH, 2023, 83 (07)
  • [18] Expression of PARP1 Gene in Breast Cancer Patients
    Ulasli, Mustafa
    Gurses, Serdar
    Cengiz, Beyhan
    Oztuzcu, Serdar
    Balakan, Ozan
    Suner, Ali
    Gogebakan, Bulent
    Igci, Mehri
    Balik, Ahmet
    Arslan, Ahmet
    Camci, Celalettin
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2013, 23 (04): : 213 - 218
  • [19] PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy
    Pawel Domagala
    Tomasz Huzarski
    Jan Lubinski
    Karol Gugala
    Wenancjusz Domagala
    Breast Cancer Research and Treatment, 2011, 127 : 861 - 869
  • [20] PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy
    Domagala, Pawel
    Huzarski, Tomasz
    Lubinski, Jan
    Gugala, Karol
    Domagala, Wenancjusz
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (03) : 861 - 869
12345